INDOCYANINE GREEN
( DrugBank: Indocyanine green / KEGG DRUG: Indocyanine green )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 22 | Moyamoya disease | 1 |
| 46 | Malignant rheumatoid arthritis | 5 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 3 |
| 278 | Huge lymphatic malformation with cervicofacial lesion | 2 |
22. Moyamoya disease
Clinical trials : 17 / Drugs : 22 - (DrugBank : 17) / Drug target genes : 33 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
278. Huge lymphatic malformation with cervicofacial lesion
Clinical trials : 19 / Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|